Juan Luciano
Analyst · Bank of Montreal
Yes, I can talk about the animal nutrition. So, we are very happy with the Neovia acquisition. We are very happy how it matches with our business. Our business was mostly North America and China, and the Neovia acquisition brought us Mexico, Central America, Brazil, Europe and Southeast Asia. So very good complement, and the more we own them, the happier we get, and the more optimistic we get about their synergies, and their ability to deliver in 2019. What had happened in the first quarter, first of all, it was a very big comp versus last year because of an issue that the industry had in vitamins that allowed everybody to sell a lot at a very high prices. So, we knew we were not going to have that. And every time you get a new transaction of the size of Neovia, you have this purchase price adjustment, this time was inventory valuation that impacted the quarter in $10 million. And then, remember, we are fighting still the tail of the lysine issue, the lysine issue is being solved, is being addressed, and we're very happy with the progress, but it still hit us in $10 million. So if you think about $20 million of noise, if you will, with a tough comp, and when you take over a company like in the case of nutrition, and Neovia, you have extra costs that you cannot properly quantify. For starters, people travel more, because you need to get to know each other, we need to start defining the synergies. Remember also that we closed at the end of January, so we closed one less -- we had one month less of that. But as we look today, we are very optimistic and very confident about delivering the EUR100 million of EBITDA that the business was supposed to deliver in 2019. And when we look at the synergies, the synergies that we were looking to deliver, the EUR50 million synergies that we were looking to deliver at year four, we are thinking now, we're estimating, we're going to deliver by the end of the year two. So, much better than expected. So, I would say, short-term noise, I look at this, can -- a little bit -- traced the parallel what happened with WILD. We took WILD in October 2014. The first quarter, not spectacular, even you guys were complaining, where do you see the revenue growth because we were shifting product mix and all that. Look at -- immediately, we started to grow faster than market, we grow organically 6%, profit growth 20% per year, and this is like four, five years after we have acquired. So, I think you're going to see the same evolution with animal nutrition, and the margin up story that we mentioned originally for Neovia is intact.